JANEL CORP (JANL) Form 8-K — Oct 22, 2026
Janel Corporation completed the acquisition of 100% of EnCor Biotechnology Inc., a Gainesville, Florida-based maker of antibodies and reagents for neurological disease research, via its Antibodies Incorporated subsidiary on October 20, 2026. The base purchase price was $17,000,000, paid as $11,960,000 in cash at closing plus a $5,040,000 subordinated promissory note. The deal was funded with operating cash, $11,000,000 immediately drawn under a newly increased $15,000,000 acquisition facility within Janel's Santander-led Senior Credit Facility (total commitments now $59,120,000), and the seller note.
Key figures
- Debt Amount
- 11000000
- Deal Value Usd
- 17000000
- Closing cash consideration
- $11,960,000
- Senior credit facility total
- $59,120,000
- Subordinated promissory note
- $5,040,000
- Employee shareholders payment
- $680,000
- Incremental acquisition facility commitment
- $15,000,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.